ResMed | RMD - Equity Capital And Reserves


ResMed reported $6.49B in Equity Capital and Reserves for its fiscal quarter ending in March of 2026.





Equity Capital And Reserves Change Date
Ansell USD 1.97B 10.2M Dec/2025
Artivion USD 450.47M 2.24M Mar/2026
AtriCure USD 491.69M 242K Mar/2026
Baxter International USD 6.04B 86M Mar/2026
Cochlear AUD 1.94B 12.2M Dec/2025
Cooper Companies USD 8.36B 124.7M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Dexcom USD 2.96B 210.9M Mar/2026
Edwards Lifesciences USD 10.33B 10.1M Mar/2026
Fisher Paykel Healthcare NZD 2.12B 129.2M Jun/2026
Globus Medical USD 4.73B 159.06M Mar/2026
Haemonetics USD 796.32M 115.13M Mar/2026
Idexx Laboratories USD 1.56B 49.28M Mar/2026
Inogen USD 197.18M 2.32M Sep/2025
Insulet USD 1.3B 212.6M Mar/2026
Integra LifeSciences USD 1.04B 1.06M Mar/2026
Intuitive Surgical USD 17.47B 349.5M Mar/2026
Medtronic USD 48.99B 128M Dec/2025
Philips EUR 11.39B 403M Mar/2026
Ramsay Health Care AUD 4.79B 916.1M Dec/2025
ResMed USD 6.49B 171.03M Mar/2026
Sigma Healthcare AUD 4.67B 3.8B Dec/2025
Sonic Healthcare AUD 8.2B 120.9M Dec/2024
Steris USD 7.18B 29.1M Mar/2026
Teleflex USD 3.08B 40.33M Mar/2026
Thermo Fisher Scientific USD 51.93B 1.6B Mar/2026